September 18, 2025

Sequential administration of abbreviated (up to one month) dual antiplatelet therapy and Ticagrelor monotherapy versus standard dual antiplatelet therapy after percutaneous coronary intervention: A meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

Discussion

This meta-analysis evaluates efficacy and safety of abbreviated dual antiplatelet therapy and Ticagrelor, suggesting possible benefits for patients.

Shorter dual antiplatelet therapy regimens may reduce bleeding complications without compromising ischemic protection.
The analysis included 22,218 patients, comparing abbreviated DAPT and long-term DAPT with no significant differences in major outcomes.
Study methodology involved a meta-analysis of existing trials evaluating outcomes of DAPT strategies in patients post-PCI.
These findings highlight the need for future research to optimize dual antiplatelet therapy approaches for better patient outcomes.

Kishor et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

September 18, 2025

View Full Paper

Ask AI

Bookmark

Authors

This meta-analysis evaluates efficacy and safety of abbreviated dual antiplatelet therapy and Ticagrelor, suggesting possible benefits for patients.

Shorter dual antiplatelet therapy regimens may reduce bleeding complications without compromising ischemic protection.
The analysis included 22,218 patients, comparing abbreviated DAPT and long-term DAPT with no significant differences in major outcomes.
Study methodology involved a meta-analysis of existing trials evaluating outcomes of DAPT strategies in patients post-PCI.
These findings highlight the need for future research to optimize dual antiplatelet therapy approaches for better patient outcomes.

Kishor et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark